131 related articles for article (PubMed ID: 32450073)
41. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence.
de Keizer PL; Packer LM; Szypowska AA; Riedl-Polderman PE; van den Broek NJ; de Bruin A; Dansen TB; Marais R; Brenkman AB; Burgering BM
Cancer Res; 2010 Nov; 70(21):8526-36. PubMed ID: 20959475
[TBL] [Abstract][Full Text] [Related]
42. High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
van den Hurk K; Balint B; Toomey S; O'Leary PC; Unwin L; Sheahan K; McDermott EW; Murphy I; van den Oord JJ; Rafferty M; FitzGerald DM; Moran J; Cummins R; MacEneaney O; Kay EW; O'Brien CP; Finn SP; Heffron CC; Murphy M; Yela R; Power DG; Regan PJ; McDermott CM; O'Keeffe A; Orosz Z; Donnellan PP; Crown JP; Hennessy BT; Gallagher WM
Melanoma Res; 2015 Jun; 25(3):189-99. PubMed ID: 25746038
[TBL] [Abstract][Full Text] [Related]
43. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P
J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445
[No Abstract] [Full Text] [Related]
44. Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status.
Nathan P; Sharma A; Lorigan P
Ann Oncol; 2013 Jun; 24(6):1712-3. PubMed ID: 23613475
[No Abstract] [Full Text] [Related]
45. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
Sabbatino F; Wang Y; Scognamiglio G; Favoino E; Feldman SA; Villani V; Flaherty KT; Nota S; Giannarelli D; Simeone E; Anniciello AM; Palmieri G; Pepe S; Botti G; Ascierto PA; Ferrone CR; Ferrone S
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851802
[TBL] [Abstract][Full Text] [Related]
46. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
Walter L; Heinzerling L
Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
[TBL] [Abstract][Full Text] [Related]
47. Lack of correlation between IGFBP7 expression and BRAF mutational status in melanoma.
Schrama D; Kneitz H; Willmes C; Adam C; Houben R; Becker JC
J Invest Dermatol; 2010 Mar; 130(3):897-8. PubMed ID: 19829302
[No Abstract] [Full Text] [Related]
48. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
49. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1.
Skorokhod A; Capper D; von Deimling A; Enk A; Helmbold P
J Am Acad Dermatol; 2012 Sep; 67(3):488-91. PubMed ID: 22890732
[No Abstract] [Full Text] [Related]
50. BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential.
Seitz-Alghrouz R; Hidalgo JV; Kayser C; Kreutz C; Technau-Hafsi K; Diaz C; von Deimling A; Timmer J; Werner M; Malkovsky M; Fisch P
J Invest Dermatol; 2018 Nov; 138(11):2489-2491. PubMed ID: 29775633
[No Abstract] [Full Text] [Related]
51. BRAF p.V600E immunohistochemistry in challenging samples: about false-positive and false-negative results.
Uguen A; Talagas M; Costa S; Marcorelles P
Hum Pathol; 2015 Jul; 46(7):1064-5. PubMed ID: 25979831
[No Abstract] [Full Text] [Related]
52. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
53. Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer.
Matsuzawa R; Morise M; Tanaka I; Hayai S; Tamiya Y; Koyama J; Hase T; Wakahara K; Kim D; Shimoyama Y; Hashimoto N
Intern Med; 2022 Mar; 61(5):703-708. PubMed ID: 34433708
[TBL] [Abstract][Full Text] [Related]
54. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
[TBL] [Abstract][Full Text] [Related]
55. BRAF p.V600E immunohistochemistry in challenging samples: about false-positive and false-negative results--reply.
Fisher KE; Cohen C; Palma JF; Longshore JW
Hum Pathol; 2015 Jul; 46(7):1065-6. PubMed ID: 25971545
[No Abstract] [Full Text] [Related]
56. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
57. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
Seghers AC; Wilgenhof S; Lebbé C; Neyns B
Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
[TBL] [Abstract][Full Text] [Related]
58. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
Schirosi L; Strippoli S; Gaudio F; Graziano G; Popescu O; Guida M; Simone G; Mangia A
BMC Cancer; 2016 Nov; 16(1):905. PubMed ID: 27863476
[TBL] [Abstract][Full Text] [Related]
59. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
60. Balloon cell melanoma possessed the ability to develop BRAF V600E mutation in cancer cells.
Chen YY; Lan CE; Yen MC; Cheng ST
Kaohsiung J Med Sci; 2021 Feb; 37(2):154-155. PubMed ID: 33118306
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]